BYSI
BYSI clinical trials: BeyondSpring Inc.
Every trial on ClinicalTrials.gov where BeyondSpring Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 6
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BYSI on the catalyst calendar · BYSI registry changes
- Primary completion Jun 1, 2029Sponsor estimatePhase 3NCT07361484Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum...BeyondSpring Pharmaceuticals Inc. · Non-Small Cell Lung CancerNot yet recruitingBYSILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2021ActualPhase 3NCT02504489Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCBeyondSpring Pharmaceuticals Inc. · Non-Small Cell Lung CancerCompletedBYSILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2018ActualPhase 3NCT03102606Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3BeyondSpring Pharmaceuticals Inc. · Chemotherapy-induced NeutropeniaCompletedBYSILeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2018ActualPhase 2NCT04345900Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2BeyondSpring Pharmaceuticals Inc. · Chemotherapy-induced NeutropeniaCompletedBYSILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2020ActualPhase 3NCT03294577Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced NeutropeniaBeyondSpring Pharmaceuticals Inc. · Chemotherapy-induced NeutropeniaUnknown statusBYSILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2018ActualPhase 2NCT04227990Plinabulin iv Solution in Prevention of TAC Induced NeutropeniaBeyondSpring Pharmaceuticals Inc. · Chemotherapy-induced NeutropeniaCompletedBYSILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2025ActualPhase 2NCT05599789Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Peking Union Medical College Hospital · Non Small Cell Lung Cancer MetastaticActive, not recruitingBYSICollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2023ActualPhase 1/Phase 2NCT03575793A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerSalma Sabbour · Lung CancerCompletedBYSICollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT05130827Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Memorial Sloan Kettering Cancer Center · Multiple MyelomaActive, not recruitingBYSICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2024ActualPhase 1NCT02812667Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)Lyudmila Bazhenova, M.D. · Non-small Cell Lung Cancer MetastaticCompletedBYSICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner